This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
5 Stocks Loved by Brokers Worth Watching Currently
by Maharathi Basu
Investors would do well to monitor stocks like ADTRAN (ADTN), Bread Financial (BFH), Owens & Minor (OMI), Bally's Corporation (BALY) and AMC Networks (AMCX) for high returns.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to benefit from positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.
Owens & Minor (OMI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 9.09% and 0.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?
by Zacks Equity Research
RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.
Will Owens & Minor (OMI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Owens & Minor (OMI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Owens & Minor (OMI) Could Rally 29.48%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 29.5% upside potential for Owens & Minor (OMI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Owens & Minor (OMI) Stock Jumps 7.6%: Will It Continue to Soar?
by Zacks Equity Research
Owens & Minor (OMI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Should Value Investors Buy Owens & Minor (OMI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
by Zacks Equity Research
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
Owens & Minor (OMI) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Owens & Minor (OMI) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BellRing Brands Inc. (BRBR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Owens & Minor, Inc. (OMI) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Owens & Minor (OMI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Investors Undervaluing Owens & Minor (OMI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Owens & Minor (OMI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 1.47% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Prestige Consumer Healthcare (PBH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 1.92% and 0.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Owens & Minor (OMI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 22.22% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 3.60%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Owens & Minor (OMI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Owens & Minor (OMI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.